Unclaimed Scholar Profile
Are you Sherman D. Padayachee? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarASIDASID-4818-2195-8462
Sherman D. Padayachee
University of Cape Town•South Africa
Faculty researcher at University of Cape Town (ZA), specializing in Agricultural, Environmental & Life Sciences. [Discipline: Agricultural, Environmental & Life Sciences] [Scholar Type: Journal Research Scientist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#SARS-CoV-2 and COVID-19 Research#COVID-19 Clinical Research Studies#Vaccine Coverage and Hesitancy#HIV Research and Treatment
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 7,198 | 3,455 |
| h-index | 8 | 6 |
| i10-index | 6 | 4 |
Annual Citation Growth
Verified Citations / Year0
2020346
2021+40%484
2022+29%622
2023+33%829
2024-8%760
2025-45%415
2026Scholarship Distribution & Proportions9 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:82% African Regional Citations (5,902) • 18% Global Research Impact (1,296)
9 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (9)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
DOI: 10.1016/s0140-6736(20)32661-1 Verified Peer-Reviewed
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Published in New England Journal of Medicine•2021
DOI: 10.1056/nejmoa2102214 Verified Peer-Reviewed
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Published in The Lancet•2021
DOI: 10.1016/s0140-6736(21)00432-3 Verified Peer-Reviewed
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Published in The Lancet HIV•2021
DOI: 10.1016/s2352-3018(21)00157-0 Verified Peer-Reviewed
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
Published in The Lancet Infectious Diseases•2022
DOI: 10.1016/s1473-3099(22)00596-5 Verified Peer-Reviewed
Showing 1 – 5 of 9 publications
1 / 2